CLINICAL TRIALS PROFILE FOR PENTAZOCINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for Pentazocine Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00125931 ↗ | Effects of Pentazocine on Manic Symptoms | Completed | Stanley Medical Research Institute | Phase 2 | 2005-09-01 | The opiate neurotransmitter system is thought to be involved in many abnormal mood states. Some researchers have suggested that changes in this system may trigger the switch to/from manic and depressive states in bipolar disorder. One problem with most of the currently available opiate medications is that they can produce addiction/dependence. A particular kind of opiate medication known as kappa-opiates may be able to produce changes in this system with much less risk of addiction. This study looks at Talwin (a combination of pentazocine and naloxone), a medication which affects the kappa and mu opiate systems. The study will examine whether two doses of Talwin affect manic symptoms in people who have been admitted to the hospital. This study will give more information about the involvement of the opiate system in bipolar disorder, and give important information for use in developing new treatments. |
| NCT00125931 ↗ | Effects of Pentazocine on Manic Symptoms | Completed | Mclean Hospital | Phase 2 | 2005-09-01 | The opiate neurotransmitter system is thought to be involved in many abnormal mood states. Some researchers have suggested that changes in this system may trigger the switch to/from manic and depressive states in bipolar disorder. One problem with most of the currently available opiate medications is that they can produce addiction/dependence. A particular kind of opiate medication known as kappa-opiates may be able to produce changes in this system with much less risk of addiction. This study looks at Talwin (a combination of pentazocine and naloxone), a medication which affects the kappa and mu opiate systems. The study will examine whether two doses of Talwin affect manic symptoms in people who have been admitted to the hospital. This study will give more information about the involvement of the opiate system in bipolar disorder, and give important information for use in developing new treatments. |
| NCT00431184 ↗ | Effects of Pentazocine Versus Lorazepam on Manic Symptoms | Completed | Stanley Medical Research Institute | Phase 2 | 2007-01-01 | Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study. We will examine whether pentazocine, an agent with kappa-opiate activity, decreases manic symptoms. |
| NCT00431184 ↗ | Effects of Pentazocine Versus Lorazepam on Manic Symptoms | Completed | Mclean Hospital | Phase 2 | 2007-01-01 | Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study. We will examine whether pentazocine, an agent with kappa-opiate activity, decreases manic symptoms. |
| NCT00499746 ↗ | The Discriminative Effects of Tramadol in Humans | Completed | National Institute on Drug Abuse (NIDA) | Phase 1/Phase 2 | 2007-11-01 | This research is part of a set of studies whose purpose is to test whether tramadol can be used for the treatment of opioid addiction. Tramadol is already available in the United States as a pain medicine marketed as Ultram. It has effects similar to morphine, and it may also have effects similar to other drugs like stimulants. The doses of tramadol used in this study are higher than those generally used for the treatment of pain. To be in this study a participant must be a user of opioids (drugs like heroin) and stimulants (drugs like cocaine), but cannot be addicted to either. The person must be between 21-55 years old, and generally healthy. Up to 12 people will take part in this study. |
| NCT01315158 ↗ | Propofol vs Propofol + Benzo/Opiates in High Risk Group | Terminated | Washington University School of Medicine | N/A | 2011-01-01 | This will be a randomized controlled trial that compares the rates of sedation related complications in high risk patients (ASA greater or equal to 3, BMI greater or equal to 30, those at risk for OSA) undergoing advanced endoscopy procedures with propofol alone compared to propofol in combination with benzodiazepines and opioids. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Pentazocine Hydrochloride
Condition Name
Clinical Trial Locations for Pentazocine Hydrochloride
Trials by Country
Clinical Trial Progress for Pentazocine Hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for Pentazocine Hydrochloride
Sponsor Name
